For help on how to get the results you want, see our search tips.
67 results
Keyword Remove keyword
Categories
Human Remove Human filter
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Direct healthcare professional communication Remove Direct healthcare professional communication filter
Summaries of opinion Remove Summaries of opinion filter
Medicine type
Generic Remove Generic filter
Additional monitoring Remove Additional monitoring filter
Accelerated assessment Remove Accelerated assessment filter
Authorisation status
Withdrawn Remove Withdrawn filter
-
List item
Human medicine European public assessment report (EPAR): Fluenz
Reassortant influenza virus (live attenuated) of the following strains:A/California/7/2009 (H1N1)pdm09 like strain, A/Victoria/361/2011 (H3N2) like strain, B/Massachusetts/2/2012 like strain, Influenza, Human, Immunization
Date of authorisation: 27/01/2011,
, Revision: 4, Withdrawn, Last updated: 03/12/2014
-
List item
Human medicine European public assessment report (EPAR): Glybera
alipogene tiparvovec, Hyperlipoproteinemia Type I
Date of authorisation: 25/10/2012,, 
, 
, Revision: 8, Withdrawn, Last updated: 30/10/2017
-
List item
Human medicine European public assessment report (EPAR): Iblias
octocog alfa, Hemophilia A
Date of authorisation: 18/02/2016,, Revision: 4, Withdrawn, Last updated: 18/02/2020
-
List item
Human medicine European public assessment report (EPAR): Imatinib medac
imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dermatofibrosarcoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myelodysplastic-Myeloproliferative Diseases, Hypereosinophilic Syndrome
Date of authorisation: 25/09/2013,
, Revision: 5, Withdrawn, Last updated: 16/10/2019
-
List item
Human medicine European public assessment report (EPAR): Imatinib Teva B.V.
imatinib mesilate, Dermatofibrosarcoma, Gastrointestinal Stromal Tumors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Date of authorisation: 15/11/2017,, Withdrawn, Last updated: 09/10/2018
-
List item
Human medicine European public assessment report (EPAR): Incivo
telaprevir, Hepatitis C, Chronic
Date of authorisation: 19/09/2011,, Revision: 19, Withdrawn, Last updated: 06/10/2016
-
List item
Human medicine European public assessment report (EPAR): Ipreziv
Azilsartan medoxomil, Hypertension
Date of authorisation: 07/12/2011,, Revision: 4, Withdrawn, Last updated: 19/12/2014
-
List item
Human medicine European public assessment report (EPAR): Ivabradine JensonR
ivabradine hydrochloride, Angina Pectoris, Heart Failure
Date of authorisation: 11/11/2016,, Withdrawn, Last updated: 20/12/2018
-
List item
Human medicine European public assessment report (EPAR): Kromeya
adalimumab, Arthritis, Rheumatoid, Arthritis, Juvenile Rheumatoid, Psoriasis, Arthritis, Psoriatic, Spondylitis, Ankylosing, Uveitis, Colitis, Ulcerative, Crohn Disease
Date of authorisation: 02/04/2019,, 
, Revision: 4, Withdrawn, Last updated: 25/03/2020
-
List item
Human medicine European public assessment report (EPAR): Lartruvo
Olaratumab, Sarcoma
Date of authorisation: 09/11/2016,
, , 
, 
, Revision: 3, Withdrawn, Last updated: 02/09/2019
-
List item
Human medicine European public assessment report (EPAR): Leflunomide Teva
leflunomide, Arthritis, Rheumatoid
Date of authorisation: 10/03/2011,, Revision: 6, Withdrawn, Last updated: 18/03/2014
-
List item
Human medicine European public assessment report (EPAR): Olanzapine Cipla (previously Olanzapine Neopharma)
olanzapine, Schizophrenia, Bipolar Disorder
Date of authorisation: 14/11/2007,, Revision: 12, Withdrawn, Last updated: 24/07/2014
-
List item
Human medicine European public assessment report (EPAR): Olysio
simeprevir, Hepatitis C, Chronic
Date of authorisation: 14/05/2014,, Revision: 13, Withdrawn, Last updated: 23/05/2018
-
List item
Human medicine European public assessment report (EPAR): Paglitaz
pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 21/03/2012,, Revision: 1, Withdrawn, Last updated: 10/03/2016
-
List item
Human medicine European public assessment report (EPAR): Picato
Ingenol mebutate, Keratosis, Actinic
Date of authorisation: 15/11/2012,, , Revision: 10, Withdrawn, Last updated: 31/07/2020
-
List item
Human medicine European public assessment report (EPAR): Pioglitazone Krka
pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 21/03/2012,, Revision: 2, Withdrawn, Last updated: 26/09/2014
-
List item
Human medicine European public assessment report (EPAR): Provenge
autologous peripheral-blood mononuclear cells including a minimum of 50 million autologous CD54+ cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor, Prostatic Neoplasms
Date of authorisation: 06/09/2013,, Revision: 1, Withdrawn, Last updated: 19/05/2015
-
List item
Human medicine European public assessment report (EPAR): Raplixa
human fibrinogen, human thrombin, Hemostasis, Surgical
Date of authorisation: 19/03/2015,, Revision: 6, Withdrawn, Last updated: 10/10/2018
-
List item
Human medicine European public assessment report (EPAR): Repso
leflunomide, Arthritis, Rheumatoid, Arthritis, Psoriatic
Date of authorisation: 14/03/2011,, Revision: 11, Withdrawn, Last updated: 21/04/2016
-
List item
Human medicine European public assessment report (EPAR): Ribavirin BioPartners
Ribavirin, Hepatitis C, Chronic
Date of authorisation: 06/04/2010,, Revision: 2, Withdrawn, Last updated: 06/05/2013
-
List item
Human medicine European public assessment report (EPAR): Ribavirin Mylan (previously Ribavirin Three Rivers)
Ribavirin, Hepatitis C, Chronic
Date of authorisation: 10/06/2010,, Revision: 10, Withdrawn, Last updated: 23/11/2020
-
List item
Human medicine European public assessment report (EPAR): Rienso
Ferumoxytol, Anemia, Kidney Failure, Chronic
Date of authorisation: 15/06/2012,, Revision: 7, Withdrawn, Last updated: 13/07/2015
-
List item
Human medicine European public assessment report (EPAR): Ristempa
pegfilgrastim, Neutropenia
Date of authorisation: 13/04/2015,, Revision: 3, Withdrawn, Last updated: 07/03/2018
-
List item
Human medicine European public assessment report (EPAR): Rituzena (previously Tuxella)
rituximab, Lymphoma, Non-Hodgkin, Microscopic Polyangiitis, Leukemia, Lymphocytic, Chronic, B-Cell, Wegener Granulomatosis
Date of authorisation: 13/07/2017,, , Revision: 7, Withdrawn, Last updated: 08/07/2019
-
List item
Human medicine European public assessment report (EPAR): Rivastigmine 3M Health Care Ltd
rivastigmine, Alzheimer Disease
Date of authorisation: 03/04/2014,, Revision: 1, Withdrawn, Last updated: 18/09/2014